Xianfeng Ren1, Yuqin Shen2, Shuyun Zheng3, JianYong Liu1,2, Xin Jiang2,4. 1. a Department of Orthopaedics , The Affiliated Hospital of Qingdao University , Qingdao , China. 2. b Department of Surgery , People's Hospital of Rizhao , Rizhao , China. 3. c Department of Medcine , People's Hospital of Zhangqiu , Zhangqiu , China. 4. d Department of Orthopaedics , People's Hospital of Weifang , Weifang , China.
Abstract
BACKGROUND AND AIMS: miR-21 has been demonstrated to play an important role in tumour progression. The aim of the present study was to analyse the correlation between miR-21 expression level and clinicopathologic features, as well as to assess the prognostic significance of miR-21 in osteosarcoma. METHODS: Eighty-four pairs of osteosarcoma and corresponding non-cancerous bone tissues were obtained, and miR-21 expression levels were detected using quantitative real-time PCR (qRT-PCR). A χ2 test was used to assess the relationship between miR-21 expression and clinicopathological features. Overall survival (OS) and disease-free survival (DFS) rates were determined by the Kaplan-Meier method and analysed by the log-rank test. The Cox proportional hazards model was used for multivariate analysis. RESULTS: qRT-PCR indicated that miR-21 expression in tumour tissues was strongly elevated compared with the adjacent corresponding non-cancerous bone tissue (7.88 ± 1.04 vs. 1.12 ± 0.37, respectively; P < 0.001). High miR-21 expression levels were linked to advanced clinical stage (P = 0.001), distant metastasis (P = 0.001), high tumour grade (P = 0.032) and large-sized tumours (P = 0.013). A higher miR-21 expression was significantly linked to shorter OS and DFS (both P < 0.001). Furthermore, a multivariate analysis confirmed that miR-21 was an independent and significant prognostic factor to predict poor OS and DFS (both P < 0.001). CONCLUSIONS: Upregulation of miR-21 was associated with poor clinicopathological characteristics. It is used as a marker of poor prognosis in patients with osteosarcoma.
BACKGROUND AND AIMS: miR-21 has been demonstrated to play an important role in tumour progression. The aim of the present study was to analyse the correlation between miR-21 expression level and clinicopathologic features, as well as to assess the prognostic significance of miR-21 in osteosarcoma. METHODS: Eighty-four pairs of osteosarcoma and corresponding non-cancerous bone tissues were obtained, and miR-21 expression levels were detected using quantitative real-time PCR (qRT-PCR). A χ2 test was used to assess the relationship between miR-21 expression and clinicopathological features. Overall survival (OS) and disease-free survival (DFS) rates were determined by the Kaplan-Meier method and analysed by the log-rank test. The Cox proportional hazards model was used for multivariate analysis. RESULTS: qRT-PCR indicated that miR-21 expression in tumour tissues was strongly elevated compared with the adjacent corresponding non-cancerous bone tissue (7.88 ± 1.04 vs. 1.12 ± 0.37, respectively; P < 0.001). High miR-21 expression levels were linked to advanced clinical stage (P = 0.001), distant metastasis (P = 0.001), high tumour grade (P = 0.032) and large-sized tumours (P = 0.013). A higher miR-21 expression was significantly linked to shorter OS and DFS (both P < 0.001). Furthermore, a multivariate analysis confirmed that miR-21 was an independent and significant prognostic factor to predict poor OS and DFS (both P < 0.001). CONCLUSIONS: Upregulation of miR-21 was associated with poor clinicopathological characteristics. It is used as a marker of poor prognosis in patients with osteosarcoma.
Authors: Sofía Jerez; Héctor Araya; Daniel Hevia; Carlos E Irarrázaval; Roman Thaler; Andre J van Wijnen; Mario Galindo Journal: Gene Date: 2019-06-06 Impact factor: 3.688
Authors: G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco Journal: Clin Transl Oncol Date: 2019-04-04 Impact factor: 3.405
Authors: Manjula Nakka; Wendy Allen-Rhoades; Yiting Li; Aaron J Kelly; Jianhe Shen; Aaron M Taylor; Donald A Barkauskas; Jason T Yustein; Irene L Andrulis; Jay S Wunder; Richard Gorlick; Paul S Meltzer; Ching C Lau; Tsz-Kwong Man Journal: Oncotarget Date: 2017-05-27